...
首页> 外文期刊>Leukemia and lymphoma >Therapy-related myelodysplastic syndrome with monosomy 5 and 7 following successful therapy for acute promyelocytic leukemia with anthracyclines.
【24h】

Therapy-related myelodysplastic syndrome with monosomy 5 and 7 following successful therapy for acute promyelocytic leukemia with anthracyclines.

机译:在与蒽环类药物成功治疗急性早幼粒细胞白血病后,出现与治疗相关的骨髓增生异常综合症(分别为5号和7号)。

获取原文
获取原文并翻译 | 示例
           

摘要

Myelodysplastic syndrome (MDS) in patients treated for acute promyelocytic leukemia (APL) is a rare event. We describe a patient with APL who developed MDS 40 months after entering complete remission (CR). Karyotypic analysis revealed monosomy 5 and 7, which are cytogenetic changes usually occurring after the use of alkylating agents. The patient had received only anthracyclines as potential leukemogenic drugs. A review of the literature on t-AML/MDS occurring after successful therapy for APL showed three similar cases. These observations suggest that anthracyclines may cause t-AML/MDS similar to that induced by alkylating agents.
机译:治疗急性早幼粒细胞白血病(APL)的患者的骨髓增生异常综合症(MDS)是罕见的事件。我们描述了进入完全缓解(CR)后40个月发展为MDS的APL患者。染色体核型分析显示单体型5和7,它们是通常在使用烷基化剂后发生的细胞遗传学变化。该患者仅接受蒽环类药物作为潜在的致白血病药物。对APL成功治疗后发生的t-AML / MDS文献的回顾显示,有3例相似的病例。这些观察结果表明,蒽环类药物可能会导致t-AML / MDS类似于烷基化剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号